Antisense oligonucleotide (ASO) therapy represents a transformative RNA-targeted approach for treating neurodegenerative diseases by selectively modulating gene expression at the molecular level. This therapeutic modality uses short, synthetic single-stranded DNA molecules designed to bind to specific messenger RNA (mRNA) sequences through Watson-Crick base pairing, thereby preventing translation or promoting degradation of the target transcript.
Antisense oligonucleotide (ASO) therapy has emerged as one of the most promising disease-modifying approaches for neurodegenerative conditions. By directly targeting the genetic basis of disease, ASOs offer the potential to slow or halt disease progression in ways that traditional small molecule drugs cannot achieve[1].
The field has matured significantly with the FDA approval of multiple ASO therapies, validating the platform for neurological diseases. Key advantages include:
ASOs exert their therapeutic effects through several molecular mechanisms:
The most common mechanism involves RNase H, an endonuclease that recognizes DNA-RNA hybrids and cleaves the RNA strand. When an ASO binds to its target mRNA, RNase H is recruited to the hybrid duplex, leading to selective degradation of the mRNA while the ASO remains intact and can repeat this process multiple times[2].
This mechanism is particularly effective for:
Alternatively, ASOs can function as steric blockers by binding to translation initiation sites, splice sites, or regulatory regions of mRNA, thereby preventing ribosome assembly or alternative splicing machinery from accessing the pre-mRNA[3].
Steric block ASOs are used for:
Newer ASO designs incorporate adenosine-to-inosine (A-to-I) editing enzymes to modify RNA sequences, enabling correction of disease-causing mutations at the RNA level[4].
To enhance stability, delivery, and target affinity, ASOs are chemically modified:
ASO therapy has shown particular promise in ALS, with tofersen (QALSODY) receiving FDA approval for SOD1 mutations. This ASO targets SOD1 mRNA, reducing mutant SOD1 protein production[5].
Tofersen (QALSODY) - Biogen
Other ALS Targets in Development:
Nusinersen (SPINRAZA) - Biogen/Ionis
Tominersen (RG6042) - Roche/Ionis
Other Huntington ASOs in Development:
ASO approaches being explored for Alzheimer disease include:
The greatest challenge for CNS-directed ASOs is achieving sufficient brain delivery. Current strategies include:
Intrathecal Administration
Conjugation Strategies
Once in the CSF, ASOs distribute throughout the CNS but require efficient uptake by target neurons. Factors affecting distribution include:
ASOs being explored in combination with:
Clinical trials ongoing for:
| Drug | Brand | Indication | Year Approved |
|---|---|---|---|
| Nusinersen | SPINRAZA | Spinal Muscular Atrophy | 2016 |
| Inotersen | TEGSEDI | hATTR Polyneuropathy | 2018 |
| Volanesorsen | WAYLIVRA | FCS | 2019 |
| Tofersen | QALSODY | SOD1-ALS | 2023 |
Similar approvals in European Union with additional post-marketing requirements
The study of Antisense Oligonucleotide Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Antisense oligonucleotides: discovery, development, and clinical applications (Dias and Stein, 2002) ↩︎
RNase H-mediated cleavage by RNase H-dependent antisense oligonucleotides (Wan and Crooke, 2010) ↩︎
Steric block antisense oligonucleotides for neurological disease (Rigo et al., 2014) ↩︎
RNA editing with CRISPR-Cas and antisense technology (Merkurjev et al., 2018) ↩︎